Medicare AdvantageCoverageMedium impact
MA06.001g, Apheresis Therapy
Independence Blue Cross·Hematology, Oncology, Nephrology +1 more·Medical Policy
Effective date
Jun 8, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.001g for Apheresis Therapy has been updated with changes to coverage position and medical necessity criteria. The policy was notified in March but became effective June 8, 2026.
Action Required
By June 8, 2026: Billing team must review updated medical necessity criteria for apheresis therapy claims under Medicare Advantage plans. Update prior authorization workflows and documentation requirements according to new coverage position. Ensure providers document medical necessity per updated criteria to avoid claim denials.